phenofAST

Antimicrobial Susceptibility Testing Solution

Health Tech & Life Sciences

Private

Company Overview

Snapshot

Founded in February 2018 by Nadav Ben-Dov and Aviram Sariel, phenofAST operates with 1–10 employees. The company has completed one funding round and secured investment from MindUP. In April 2021, MindUP invested in phenofAST, marking a key milestone for the company.

Business overview

phenofAST develops a rapid and cost-effective clinical diagnostic solution for antibiotic susceptibility testing, aiming to provide definitive results within four hours of a positive culture. The company's core technology leverages new physics-based methods, detecting cell division through laser light interferences, powered by AI analysis. This solution is designed for use in any microbiology lab, offering a modular, green, and low-waste operation. phenofAST serves healthcare providers, laboratories, and pharmaceutical companies, addressing the critical need for faster antibiotic susceptibility testing to combat antibiotic-resistant bacteria and improve patient outcomes.

Strategic signal

In June 2021, MindUP announced its investment in phenofAST, highlighting the startup as its 14th portfolio company. This investment signals validation for phenofAST's innovative approach to antimicrobial susceptibility testing and suggests potential for accelerated development and market penetration within the health tech and life sciences sector.

Company Intelligence Q&A

What is phenofAST's core technology?: phenofAST utilizes a new physics-based technology that detects cell division through laser light interferences, powered by AI analysis, to provide rapid antibiotic susceptibility testing.
When was phenofAST founded?: phenofAST was founded in February 2018.
What problem does phenofAST aim to solve?: phenofAST aims to address the challenge of slow antibiotic susceptibility testing, which typically takes 2 to 3 days, by providing definitive results within 4 hours to minimize antimicrobial resistance and improve treatment efficacy.
Who are the founders of phenofAST?: phenofAST was co-founded by Nadav Ben-Dov and Aviram Sariel.

External links

phenofAST — full profile (machine-readable)

phenofAST has developed a fast and affordable clinical diagnostic solution for antibiotic susceptibility testing, providing definitive test results within 4 hours from a positive culture. Antibiotic susceptibility tests (AST) can take 2 to 3 days to produce definitive results, and with the accelerated spread of antibiotic-resistant bacteria, inappropriate antibiotic treatment results in mortality, morbidity, and higher healthcare costs across all stakeholders. phenofAST is the only company to have completely new & innovative physics-based technology, detecting cell division through laser light interferences, powered by AI analysis. phenofASTs solution provides same day AST test results in a cost effective way for a wide range of indications. This solution is applicable to any microbiology lab due to it's modular design – fit any lab space and needs, Green, minimal waste operation and low price of disposable testing cassette. With phenofAST solution, the microbiology lab will be able to provide the physician with the AST results, enabling the physician to adjust the antibiotic treatment on the same day that the patient was admitted, minimizing AMR ( antimicrobial resistance) and maximizing the right and effective treatment needed. Clinical validations done so far provided very high agreement with the gold standard. phenofAST goal is to become the Standard of Practice in antibiotic susceptibility testing, proving fast, cost-effective and wide-range solution for healthcare providers and payers.

Facts
Name	phenofAST
One-liner	Antimicrobial Susceptibility Testing Solution
Type	Startup
Primary sector	Health Tech & Life Sciences
Founded	2018
Employees	1-10
Employees (exact)	4
HQ / location	Haifa, Haifa, Israel, North District
Product stage	Beta
Website	https://www.phenofast.com/
LinkedIn	https://www.linkedin.com/company/71559460/
IL Registrar	515612885

Facts

Name

phenofAST

One-liner

Antimicrobial Susceptibility Testing Solution

Type

Startup

Primary sector

Health Tech & Life Sciences

Founded

2018

Employees

1-10

Employees (exact)

HQ / location

Haifa, Haifa, Israel, North District

Product stage

Beta

Website

https://www.phenofast.com/

https://www.linkedin.com/company/71559460/

IL Registrar

515612885

Classification
Sectors	Health Tech & Life Sciences, Pharma & Medical Biotechnology, Test Diagnostics & Screening
Core technology	Artificial Intelligence, Image Recognition, Sensing, Laser, Optic, Platforms & Interfaces, Software
Target customers	Healthcare & Life Sciences, Healthcare, Insurance Companies, Providers, Laboratories, Patients, Medical Devices Industry, Medical Equipment, Life Sciences, Biotechnology
Business models	B2B
Tags	real-time, optics, artificial-intelligence, lasers, sensors, healthcare-providers, laboratories, pharmaceuticals

Classification

Sectors

Health Tech & Life Sciences, Pharma & Medical Biotechnology, Test Diagnostics & Screening

Core technology

Artificial Intelligence, Image Recognition, Sensing, Laser, Optic, Platforms & Interfaces, Software

Target customers

Healthcare & Life Sciences, Healthcare, Insurance Companies, Providers, Laboratories, Patients, Medical Devices Industry, Medical Equipment, Life Sciences, Biotechnology

Business models

B2B

Name	Role	Founder
Eliane Markowitz	CEO
Nadav Ben-Dov	Founder & CTO	yes
Aviram Sariel	Co-founder	yes

phenofAST

Company Overview

Snapshot

Business overview

Strategic signal

Company Intelligence Q&A

External links

Generate Slim Page